The effects of alternative treatments for HIV disease on recommended pharmacological regimens.
The use of alternative treatments for HIV disease was assessed before and after the introduction of highly active antiretroviral therapy (HAART) by the use of a standardised questionnaire. These data were related to epidemiological, clinical and laboratory parameters and compliance levels to recommended antiretroviral and anti-Pneumocystis carinii regimens. Compared with the 476 evaluable patients interviewed during the first 9 months of 1996, the 549 evaluable subjects screened in January-September 1998 showed less frequent recourse to alternative treatments (22.8 vs. 35.7% of patients; P < 0.001). A significant correlation between use of alternatives, poor compliance to antiretroviral drugs and anti-P. carinii chemoprophylaxis and clinical and immunological progression of HIV disease was shown in 1996, but was not maintained in 1998. No relevant differences were found in the selection of most non-conventional treatments and in the number of strategies followed and their duration of use. Unorthodox treatments were used by most patients concurrently rather than instead of official therapeutic regimens. No correlation was found between the use of alternative treatment and the patients' age, gender, type of risk for HIV disease and duration of HIV seropositivity. The correlations between alternative and official treatments for HIV disease before and during the HAART era shows that a considerable percentage of patients still resort to alternatives in 1998 compared with 1996 but that this does not interfere with compliance with recommended pharmacological regimens or the progression of the disease.
Manfredi
R
R
Department of Clinical and Experimental Medicine, University of Bologna, S. Orsola Hospital, Italy.
Chiodo
F
F
D019380:Anti-HIV Agents / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D000529:Complementary Therapies; D003625:Data Collection; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D016720:Pneumocystis Infections / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control / Q000628:therapy
D019380:Anti-HIV Agents; D000935:Antifungal Agents